Amgen (AMGN) Stock Insights
AMGN$451.83+3.88 +0.87%
$244.27B
Market Cap
27.62
P/E
19.60
Forward P/E
53
Score
Amgen (AMGN) Stock Insights
AMGN price $451.83 +3.88 +0.87%
- Ticker
- AMGN
- Price
- $451.83
- Change
- +3.88 +0.87%
- Market cap ?
- $244.27B
- P/E ?
- 27.62
- Forward P/E ?
- 19.60
- Dividend yield ?
- 2.22%
- Beta ?
- 0.41
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stocklytics score
- 53
- Value
- 37
- Quality
- 68
- Growth
- 55
Stocklytics score rationale: value 37, quality 68, growth 55.
Financials
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| 22991000000 | 22849000000 | 23747000000 | 23362000000 | 25424000000 | 25979000000 | 26323000000 | 28190000000 | 33424000000 | 36741000000 |
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience…
Fair value
AMGN fair value $599.77. Price $451.83. Price is 25% below fair value.
Below fair value, and cheaper than usual. A larger discount than on 64% of days in the past 5 years.
Fair value is an estimate of what one share is worth if future cash flows arrive as modeled. It is not a forecast of the share price. How discounted cash flow works.
Calculated with a 10-year free-cash-flow discount. Starting free cash flow 10.18B. Growth 7.18%. When analyst earnings forecasts are available, free cash flow in those years is forecast earnings times the company's usual conversion of earnings into free cash flow, kept between 60% and 130%. Years with fewer than 3 analyst estimates are left out. Growth then fades in a straight line to terminal growth by year 10, starting from the last well-covered year's growth, or from the pace across those years when the final year slows sharply, kept between 0% and 20%. Without those forecasts, year-1 growth is analyst revenue growth for the next full fiscal year, or 5-year historical revenue growth when that forecast is missing, held for five years, then fading in a straight line to terminal growth by year 10. Terminal growth 3.00%. Discount rate 8.70% (beta 0.8). Beta is kept between 0.8 and 2.0, which on its own would make the discount rate 8.7% to 15.3%. The rate is then capped at 12%. A cap is used because a discount above 12% pushes higher-beta stocks further from the price. The discount rate stays at least 5 percentage points above terminal growth. Shares 540.63M. Net debt 45.48B. The earnings value is next-12-months earnings per share, or trailing earnings when that forecast is missing, times the median P/E of the company's industry. That median uses listed stocks worth at least $10 billion with a positive P/E of 100 or below, and the industry needs at least eight of them. Otherwise the sector median is used when that group also has at least eight, then the market median of those large companies. The multiple used is the lower of that median and 1.25 times the stock's own 10-year median P/E, then kept between 8 and 30. If the stock has no 10-year median, the peer median is kept between 8 and 30. Fair value is the average of the cash-flow value and the earnings value when both exist. Card and credit companies use the earnings value only, because changes in customer receivables distort free cash flow. Model uncertainty is high when fair value is more than 60% from the price, or when most of the cash-flow value sits after year 10.
Earnings
| Date | EPS actual | EPS estimate | Revenue | Revenue estimate |
|---|---|---|---|---|
| 2026-11-03 | — | 5.79 | — | 10.08B |
| 2026-08-04 | 6.29 | 5.62 | 10.05B | 9.43B |
| 2026-04-30 | 5.15 | 4.77 | 8.62B | 8.58B |
| 2026-02-03 | 5.29 | 4.73 | 9.87B | 9.47B |
| 2025-11-04 | 5.64 | 5.02 | 9.56B | 8.97B |
| 2025-08-05 | 6.02 | 5.28 | 9.17B | 8.94B |
| 2025-05-01 | 4.90 | 4.27 | 8.15B | 8.06B |
| 2025-02-04 | 5.31 | 5.04 | 9.09B | 8.88B |
| 2024-10-30 | 5.58 | 5.11 | 8.50B | 8.50B |
| 2024-08-06 | 4.97 | 4.98 | 8.39B | 8.35B |
| 2024-05-02 | 3.96 | 3.88 | 7.45B | 7.45B |
| 2024-02-06 | 4.71 | 4.59 | 8.20B | 8.13B |
| 2023-10-31 | 4.96 | 4.65 | 6.90B | 6.62B |
| 2023-08-03 | 5.00 | 4.44 | 6.99B | 6.68B |
| 2023-04-27 | 3.98 | 3.85 | 6.11B | 6.65B |
| 2023-01-31 | 4.09 | 4.04 | 6.84B | 6.74B |
| 2022-11-03 | 4.70 | 4.44 | 6.65B | 6.56B |
| 2022-08-04 | 4.65 | 4.40 | 6.59B | 6.53B |
| 2022-04-27 | 4.25 | 4.22 | 6.24B | 6.07B |
| 2022-02-07 | 4.36 | 4.14 | 6.85B | 6.87B |
| 2021-11-02 | 4.67 | 4.22 | 6.71B | 6.71B |
| 2021-08-03 | 4.38 | 4.13 | 6.53B | 6.45B |
| 2021-04-27 | 3.70 | 4.05 | 5.90B | 6.29B |
| 2021-02-02 | 3.81 | 3.36 | 6.63B | 5.81B |
| 2020-10-28 | 4.37 | 3.81 | 6.42B | 5.60B |
| 2020-07-28 | 4.25 | 3.81 | 6.21B | 5.59B |
| 2020-04-30 | 4.17 | 3.70 | 6.16B | 5.56B |
| 2020-01-30 | 3.64 | 3.47 | 6.20B | 5.91B |
| 2019-10-29 | 3.66 | 3.53 | 5.74B | 5.53B |
| 2019-07-30 | 3.97 | 3.59 | 5.87B | 5.31B |
| 2019-04-30 | 3.56 | 3.48 | 5.56B | 5.43B |
| 2019-01-29 | 3.42 | 3.27 | 6.23B | 5.96B |
| 2018-10-30 | 3.69 | 3.45 | 5.90B | 5.52B |
| 2018-07-26 | 3.83 | 3.54 | 6.06B | 5.60B |
| 2018-04-24 | 3.47 | 3.23 | 5.55B | 5.19B |
| 2018-02-01 | 2.89 | 3.04 | 5.80B | 6.08B |
| 2017-10-25 | 3.27 | 3.11 | 5.77B | 5.49B |
| 2017-07-25 | 3.27 | 3.11 | 5.81B | 5.53B |
| 2017-04-26 | 3.15 | 3.00 | 5.46B | 5.20B |
| 2017-02-02 | 2.89 | 2.79 | 5.96B | 5.76B |
Dividends
Yield 2.20%. Payout ratio 60.45%. Frequency Quarterly.
Safety score 82/100 · Safe. Payout ratio is 60% of earnings. Dividends use a moderate share of free cash flow. Dividends were paid in 16 separate years. Yield is 2.2%, in a range that is usually sustainable.
| Ex-date | Dividend | Record | Payment | Frequency |
|---|---|---|---|---|
| 2026-08-21 | $2.52 | 2026-08-21 | 2026-09-11 | Quarterly |
| 2026-05-15 | $2.52 | 2026-05-15 | 2026-06-05 | Quarterly |
| 2026-02-13 | $2.52 | 2026-02-13 | 2026-03-06 | Quarterly |
| 2025-11-21 | $2.38 | 2025-11-21 | 2025-12-12 | Quarterly |
| 2025-08-22 | $2.38 | 2025-08-22 | 2025-09-12 | Quarterly |
| 2025-05-16 | $2.38 | 2025-05-16 | 2025-06-06 | Quarterly |
| 2025-02-14 | $2.38 | 2025-02-14 | 2025-03-07 | Quarterly |
| 2024-11-18 | $2.25 | 2024-11-18 | 2024-12-09 | Quarterly |
| 2024-08-16 | $2.25 | 2024-08-16 | 2024-09-06 | Quarterly |
| 2024-05-16 | $2.25 | 2024-05-17 | 2024-06-07 | Quarterly |
| 2024-02-15 | $2.25 | 2024-02-16 | 2024-03-07 | Quarterly |
| 2023-11-16 | $2.13 | 2023-11-17 | 2023-12-08 | Quarterly |
| 2023-08-17 | $2.13 | 2023-08-18 | 2023-09-08 | Quarterly |
| 2023-05-17 | $2.13 | 2023-05-18 | 2023-06-08 | Quarterly |
| 2023-02-14 | $2.13 | 2023-02-15 | 2023-03-08 | Quarterly |
| 2022-11-16 | $1.94 | 2022-11-17 | 2022-12-08 | Quarterly |
| 2022-08-17 | $1.94 | 2022-08-18 | 2022-09-08 | Quarterly |
| 2022-05-16 | $1.94 | 2022-05-17 | 2022-06-08 | Quarterly |
| 2022-02-14 | $1.94 | 2022-02-15 | 2022-03-08 | Quarterly |
| 2021-11-15 | $1.76 | 2021-11-16 | 2021-12-08 | Quarterly |
| 2021-08-16 | $1.76 | 2021-08-17 | 2021-09-08 | Quarterly |
| 2021-05-14 | $1.76 | 2021-05-17 | 2021-06-08 | Quarterly |
| 2021-02-11 | $1.76 | 2021-02-15 | 2021-03-08 | Quarterly |
| 2020-11-13 | $1.60 | 2020-11-16 | 2020-12-08 | Quarterly |
| 2020-08-14 | $1.60 | 2020-08-17 | 2020-09-08 | Quarterly |
| 2020-05-15 | $1.60 | 2020-05-18 | 2020-06-08 | Quarterly |
| 2020-02-13 | $1.60 | 2020-02-14 | 2020-03-06 | Quarterly |
| 2019-11-14 | $1.45 | 2019-11-15 | 2019-12-06 | Quarterly |
| 2019-08-14 | $1.45 | 2019-08-15 | 2019-09-06 | Quarterly |
| 2019-05-16 | $1.45 | 2019-05-17 | 2019-06-07 | Quarterly |
| 2019-02-14 | $1.45 | 2019-02-15 | 2019-03-08 | Quarterly |
| 2018-11-15 | $1.32 | 2018-11-16 | 2018-12-07 | Quarterly |
| 2018-08-16 | $1.32 | 2018-08-17 | 2018-09-07 | Quarterly |
| 2018-05-16 | $1.32 | 2018-05-17 | 2018-06-08 | Quarterly |
| 2018-02-14 | $1.32 | 2018-02-15 | 2018-03-08 | Quarterly |
| 2017-11-16 | $1.15 | 2017-11-17 | 2017-12-08 | Quarterly |
| 2017-08-15 | $1.15 | 2017-08-17 | 2017-09-08 | Quarterly |
| 2017-05-15 | $1.15 | 2017-05-17 | 2017-06-08 | Quarterly |
| 2017-02-13 | $1.15 | 2017-02-15 | 2017-03-08 | Quarterly |
| 2016-11-14 | $1.00 | 2016-11-16 | 2016-12-08 | Quarterly |
| 2016-08-15 | $1.00 | 2016-08-17 | 2016-09-08 | Quarterly |
| 2016-05-13 | $1.00 | 2016-05-17 | 2016-06-08 | Quarterly |
| 2016-02-11 | $1.00 | 2016-02-16 | 2016-03-08 | Quarterly |
| 2015-11-12 | $0.79 | 2015-11-16 | 2015-12-07 | Quarterly |
| 2015-08-13 | $0.79 | 2015-08-17 | 2015-09-08 | Quarterly |
| 2015-05-12 | $0.79 | 2015-05-14 | 2015-06-05 | Quarterly |
| 2015-02-10 | $0.79 | 2015-02-12 | 2015-03-06 | Quarterly |
| 2014-11-10 | $0.61 | 2014-11-13 | 2014-12-05 | Quarterly |
| 2014-08-12 | $0.61 | 2014-08-14 | 2014-09-05 | Quarterly |
| 2014-05-13 | $0.61 | 2014-05-15 | 2014-06-06 | Quarterly |
| 2014-02-11 | $0.61 | 2014-02-13 | 2014-03-07 | Quarterly |
| 2013-11-12 | $0.47 | 2013-11-14 | 2013-12-06 | Quarterly |
| 2013-08-14 | $0.47 | 2013-08-16 | 2013-09-06 | Quarterly |
| 2013-05-14 | $0.47 | 2013-05-16 | 2013-06-07 | Quarterly |
| 2013-02-11 | $0.47 | 2013-02-13 | 2013-03-07 | Quarterly |
| 2012-11-13 | $0.36 | 2012-11-15 | 2012-12-07 | Quarterly |
| 2012-08-14 | $0.36 | 2012-08-16 | 2012-09-07 | Quarterly |
| 2012-05-14 | $0.36 | 2012-05-16 | 2012-06-07 | Quarterly |
| 2012-02-13 | $0.36 | 2012-02-15 | 2012-03-07 | Quarterly |
| 2011-11-15 | $0.28 | 2011-11-17 | 2011-12-08 | Quarterly |
| 2011-08-16 | $0.28 | 2011-08-18 | 2011-09-08 | Quarterly |
Insider trades
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| 2027-08-07 | Dittrich Thomas J.W. | Other | 17.20K | $410.95 | 7.07M |
| 2026-10-26 | Gibbs David W | Other | 0 | — | — |
| 2026-09-01 | Dittrich Thomas J.W. | Other | 0 | — | — |
| 2026-08-13 | Khosla Rachna | Buy | 1.25K | $162.60 | 203.58K |
| 2026-08-13 | Khosla Rachna | Sell | 1.25K | $416.43 | 521.36K |
| 2026-08-13 | Khosla Rachna | Sell | 1.25K | $162.60 | 203.58K |
| 2026-08-11 | Khosla Rachna | Sell | 2.00K | $412.57 | 825.13K |
| 2026-08-07 | Busch Matthew C. | Buy | 730 | — | — |
| 2026-08-07 | ISHRAK OMAR | Buy | 85 | — | — |
| 2026-08-07 | HOLLEY CHARLES M | Buy | 103 | — | — |
| 2026-08-07 | Drake Michael V | Buy | 64 | — | — |
| 2026-08-06 | Miller Derek | Buy | 2.07K | $162.60 | 336.42K |
| 2026-08-06 | Miller Derek | Buy | 1.82K | $177.46 | 323.15K |
| 2026-08-06 | Miller Derek | Sell | 1.82K | $402.54 | 733.03K |
| 2026-08-06 | Miller Derek | Sell | 2.07K | $162.60 | 336.42K |
| 2026-08-06 | Miller Derek | Sell | 1.82K | $177.46 | 323.15K |
| 2026-08-06 | Grygiel Nancy A. | Buy | 1.97K | $177.46 | 349.60K |
| 2026-08-06 | Grygiel Nancy A. | Buy | 1.00K | $177.31 | 177.31K |
| 2026-08-06 | Grygiel Nancy A. | Sell | 1.00K | $402.16 | 402.16K |
| 2026-08-06 | Grygiel Nancy A. | Sell | 1.00K | $177.31 | 177.31K |
| 2026-08-06 | Grygiel Nancy A. | Sell | 1.97K | $177.46 | 349.60K |
| 2026-05-19 | MILES AMY E | Buy | 665 | — | — |
| 2026-05-19 | Kullman Ellen Jamison | Buy | 665 | — | — |
| 2026-05-19 | Klotman Mary E. | Buy | 665 | — | — |
| 2026-05-19 | Jacks Tyler | Buy | 665 | — | — |
| 2026-05-19 | ISHRAK OMAR | Buy | 665 | — | — |
| 2026-05-19 | HOLLEY CHARLES M | Buy | 665 | — | — |
| 2026-05-19 | Garland Greg C. | Buy | 665 | — | — |
| 2026-05-19 | ECKERT ROBERT | Buy | 665 | — | — |
| 2026-05-19 | Druker Brian | Buy | 665 | — | — |
| 2026-05-19 | Drake Michael V | Buy | 665 | — | — |
| 2026-05-19 | Austin Wanda M | Buy | 665 | — | — |
| 2026-05-07 | Busch Matthew C. | Sell | 41 | $331.11 | 13.58K |
| 2026-05-07 | Santos Esteban | Sell | 522 | $331.11 | 172.84K |
| 2026-05-07 | REESE DAVID M | Sell | 556 | $331.11 | 184.10K |
| 2026-05-07 | Miller Derek | Sell | 151 | $331.11 | 50.00K |
| 2026-05-07 | Khosla Rachna | Sell | 93 | $331.11 | 30.79K |
| 2026-05-07 | Grygiel Nancy A. | Sell | 88 | $331.11 | 29.14K |
| 2026-05-07 | Griffith Peter H. | Sell | 556 | $331.11 | 184.10K |
| 2026-05-07 | Graham Jonathan P | Sell | 499 | $331.11 | 165.22K |
| 2026-05-07 | Gordon Murdo | Sell | 615 | $331.11 | 203.63K |
| 2026-05-07 | Bradway Robert A | Sell | 2.08K | $331.11 | 688.38K |
| 2026-05-07 | Bradner James E. | Sell | 446 | $331.11 | 147.68K |
| 2026-05-06 | Bradner James E. | Sell | 407 | $329.59 | 134.14K |
| 2026-05-06 | Bradway Robert A | Sell | 1.70K | $329.59 | 560.96K |
| 2026-05-06 | Busch Matthew C. | Sell | 50 | $329.59 | 16.48K |
| 2026-05-06 | Gordon Murdo | Sell | 502 | $329.59 | 165.45K |
| 2026-05-06 | Graham Jonathan P | Sell | 408 | $329.59 | 134.47K |
| 2026-05-06 | Griffith Peter H. | Sell | 502 | $329.59 | 165.45K |
| 2026-05-06 | Grygiel Nancy A. | Sell | 76 | $329.59 | 25.05K |
| 2026-05-06 | Khosla Rachna | Sell | 79 | $329.59 | 26.04K |
| 2026-05-06 | Miller Derek | Sell | 123 | $329.59 | 40.54K |
| 2026-05-06 | REESE DAVID M | Sell | 454 | $329.59 | 149.63K |
| 2026-05-06 | Santos Esteban | Sell | 427 | $329.59 | 140.73K |
| 2026-05-05 | Bradner James E. | Buy | 3.34K | — | — |
| 2026-05-05 | Bradner James E. | Buy | 21.77K | $329.59 | 7.18M |
| 2026-05-05 | Bradway Robert A | Buy | 12.14K | — | — |
| 2026-05-05 | Bradway Robert A | Buy | 79.18K | $329.59 | 26.10M |
| 2026-05-05 | Busch Matthew C. | Buy | 455 | — | — |
| 2026-05-05 | Busch Matthew C. | Buy | 2.97K | $329.59 | 978.55K |
| 2026-05-05 | Gordon Murdo | Buy | 3.64K | — | — |
| 2026-05-05 | Gordon Murdo | Buy | 23.75K | $329.59 | 7.83M |
| 2026-05-05 | Graham Jonathan P | Buy | 2.61K | — | — |
| 2026-05-05 | Graham Jonathan P | Buy | 17.02K | $329.59 | 5.61M |
| 2026-05-05 | Griffith Peter H. | Buy | 3.64K | — | — |
| 2026-05-05 | Griffith Peter H. | Buy | 23.75K | $329.59 | 7.83M |
| 2026-05-05 | Grygiel Nancy A. | Buy | 485 | — | — |
| 2026-05-05 | Grygiel Nancy A. | Buy | 3.17K | $329.59 | 1.04M |
| 2026-05-05 | Khosla Rachna | Buy | 500 | — | — |
| 2026-05-05 | Khosla Rachna | Buy | 3.27K | $329.59 | 1.08M |
| 2026-05-05 | Miller Derek | Buy | 910 | — | — |
| 2026-05-05 | Miller Derek | Buy | 5.94K | $329.59 | 1.96M |
| 2026-05-05 | REESE DAVID M | Buy | 2.91K | — | — |
| 2026-05-05 | REESE DAVID M | Buy | 19.00K | $329.59 | 6.26M |
| 2026-05-05 | Santos Esteban | Buy | 2.73K | — | — |
| 2026-05-05 | Santos Esteban | Buy | 17.81K | $329.59 | 5.87M |
| 2026-05-05 | ISHRAK OMAR | Buy | 106 | — | — |
| 2026-05-05 | HOLLEY CHARLES M | Buy | 129 | — | — |
| 2026-05-05 | Drake Michael V | Buy | 80 | — | — |
| 2026-05-04 | Grygiel Nancy A. | Sell | 1.24K | $323.73 | 400.45K |
| 2026-05-02 | Santos Esteban | Sell | 697 | $329.82 | 229.88K |
| 2026-05-02 | Santos Esteban | Sell | 641 | $329.82 | 211.41K |
| 2026-05-02 | REESE DAVID M | Sell | 746 | $329.82 | 246.05K |
| 2026-05-02 | REESE DAVID M | Sell | 687 | $329.82 | 226.59K |
| 2026-05-02 | Miller Derek | Sell | 167 | $329.82 | 55.08K |
| 2026-05-02 | Miller Derek | Sell | 198 | $329.82 | 65.30K |
| 2026-05-02 | Khosla Rachna | Sell | 117 | $329.82 | 38.59K |
| 2026-05-02 | Khosla Rachna | Sell | 108 | $329.82 | 35.62K |
| 2026-05-02 | Grygiel Nancy A. | Sell | 126 | $329.82 | 41.56K |
| 2026-05-02 | Grygiel Nancy A. | Sell | 116 | $329.82 | 38.26K |
| 2026-05-02 | Griffith Peter H. | Sell | 746 | $329.82 | 246.05K |
| 2026-05-02 | Griffith Peter H. | Sell | 687 | $329.82 | 226.59K |
| 2026-05-02 | Graham Jonathan P | Sell | 647 | $329.82 | 213.39K |
| 2026-05-02 | Graham Jonathan P | Sell | 610 | $329.82 | 201.19K |
| 2026-05-02 | Gordon Murdo | Sell | 830 | $329.82 | 273.75K |
| 2026-05-02 | Gordon Murdo | Sell | 763 | $329.82 | 251.65K |
| 2026-05-02 | Busch Matthew C. | Sell | 30 | $329.82 | 9.89K |
| 2026-05-02 | Busch Matthew C. | Sell | 38 | $329.82 | 12.53K |
| 2026-05-02 | Bradway Robert A | Sell | 2.63K | $329.82 | 867.76K |
| 2026-05-02 | Bradway Robert A | Sell | 2.43K | $329.82 | 800.14K |
Institutional holders
Latest filed quarter: Q2 2026.
Institutions holding: 3.25K, holders +7 vs prior quarter. Ownership 85.56%.
| Holder | Shares | Change | Change % | Value |
|---|---|---|---|---|
| BLACKROCK, INC. | 49.36M | 2.26M | +4.80% | 17.87B |
| VANGUARD CAPITAL MANAGEMENT LLC | 35.25M | 235.87K | +0.67% | 12.76B |
| STATE STREET CORP | 30.56M | 12.05K | +0.04% | 11.07B |
| CAPITAL WORLD INVESTORS | 29.08M | -213.01K | -0.73% | 10.53B |
| INVESCO LTD. | 16.32M | 5.01M | +44.25% | 5.91B |
| GEODE CAPITAL MANAGEMENT, LLC | 15.70M | 265.54K | +1.72% | 5.67B |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 15.03M | 2.26M | +17.70% | 5.44B |
| SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. | 15.03M | 15.03M | New | 5.44B |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 14.85M | 232.22K | +1.59% | 5.38B |
| MORGAN STANLEY | 13.65M | -2.18M | -13.78% | 4.94B |
| WELLS FARGO & COMPANY/MN | 7.24M | 147.45K | +2.08% | 2.62B |
| PRIMECAP MANAGEMENT CO/CA/ | 6.76M | -2.12M | -23.86% | 2.45B |
| CAPITAL RESEARCH GLOBAL INVESTORS | 6.27M | -682.72K | -9.82% | 2.27B |
| NORTHERN TRUST CORP | 6.20M | -16.84K | -0.27% | 2.25B |
| NORGES BANK | 5.63M | 5.63M | New | 2.04B |
| UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC | 5.39M | 605.93K | +12.66% | 1.95B |
| BANK OF AMERICA CORP /DE/ | 5.06M | -62.20K | -1.21% | 1.83B |
| ROYAL BANK OF CANADA | 4.33M | -142.66K | -3.19% | 1.57B |
| GOLDMAN SACHS GROUP INC | 4.13M | -89.26K | -2.12% | 1.50B |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.96M | 2.09M | +111.92% | 1.43B |
| AMUNDI | 3.89M | 512.88K | +15.19% | 1.41B |
| LEGAL & GENERAL GROUP PLC | 3.82M | -53.92K | -1.39% | 1.38B |
| BANK OF NEW YORK MELLON CORP | 3.70M | -97.86K | -2.58% | 1.34B |
| JPMORGAN CHASE & CO | 3.59M | -3.69M | -50.69% | 1.29B |
| FMR LLC | 3.49M | -284.61K | -7.54% | 1.26B |
Insights
- Revenue by product
- Revenue by region
| Period | Value |
|---|---|
| FY2010 | Aranesp - International: 1383000000.0, Aranesp - U.S.: 1103000000.0, ENBREL - Canada: 230000000.0, ENBREL - U.S.: 3304000000.0, EPOGEN - U.S.: 2524000000.0, Mimpara - International: 255000000.0, Neulasta - International: 904000000.0, Neulasta - U.S.: 2654000000.0, NEUPOGEN - International: 354000000.0, NEUPOGEN - U.S.: 932000000.0, Nplate - International: 100000000.0, Nplate - U.S.: 129000000.0, Other - International: 0.0, Other - U.S.: 0.0, Prolia - International: 7000000.0, Prolia - U.S.: 26000000.0, Sensipar - U.S.: 459000000.0, Vectibix - International: 173000000.0, Vectibix - U.S.: 115000000.0, XGEVA - U.S.: 8000000.0 |
| FY2012 | Aranesp: 2040000000.0, ENBREL: 4236000000.0, EPOGEN: 1941000000.0, Neulasta: 4092000000.0, NEUPOGEN: 1260000000.0, Nplate: 368000000.0, Prolia: 472000000.0, Sensipar Mimpara: 950000000.0, Vectibix: 359000000.0, XGEVA: 748000000.0 |
| FY2013 | Aranesp: 1911000000.0, ENBREL: 4551000000.0, EPOGEN: 1953000000.0, Kyprolis: 73000000.0, Neulasta: 4392000000.0, NEUPOGEN: 1398000000.0, Nplate: 427000000.0, Prolia: 744000000.0, Sensipar Mimpara: 1089000000.0, Vectibix: 389000000.0, XGEVA: 1019000000.0 |
| FY2014 | Aranesp: 1930000000.0, BLINCYTO: 3000000.0, ENBREL: 4688000000.0, EPOGEN: 2031000000.0, Kyprolis: 331000000.0, Neulasta: 4596000000.0, NEUPOGEN: 1159000000.0, Nplate: 469000000.0, Prolia: 1030000000.0, Sensipar Mimpara: 1158000000.0, Vectibix: 505000000.0, XGEVA: 1221000000.0 |
| FY2015 | Aranesp: 1951000000.0, ENBREL: 5364000000.0, EPOGEN: 1856000000.0, Kyprolis: 512000000.0, Neulasta: 4715000000.0, NEUPOGEN: 1049000000.0, Nplate: 525000000.0, Prolia: 1312000000.0, Sensipar Mimpara: 1415000000.0, Vectibix: 549000000.0, XGEVA: 1405000000.0 |
| FY2016 | Aranesp: 2093000000.0, BLINCYTO: 115000000.0, ENBREL: 5965000000.0, EPOGEN: 1282000000.0, Kyprolis: 692000000.0, Neulasta: 4648000000.0, NEUPOGEN: 765000000.0, Nplate: 584000000.0, Prolia: 1635000000.0, Repatha: 141000000.0, Sensipar Mimpara: 1582000000.0, Vectibix: 611000000.0, XGEVA: 1529000000.0 |
| FY2017 | Aranesp: 2053000000.0, BLINCYTO: 175000000.0, ENBREL: 5433000000.0, EPOGEN: 1096000000.0, Kyprolis: 835000000.0, Neulasta: 4534000000.0, NEUPOGEN: 549000000.0, Nplate: 642000000.0, Prolia: 1968000000.0, Repatha: 319000000.0, Sensipar Mimpara: 1718000000.0, Vectibix: 642000000.0, XGEVA: 1575000000.0 |
| FY2018 | Aranesp: 1877000000.0, ENBREL: 5014000000.0, EPOGEN: 1010000000.0, Neulasta: 4475000000.0, Other Products: 4306000000.0, Product and Service, Other: 1214000000.0, Prolia: 2291000000.0, Sensipar Mimpara: 1774000000.0, XGEVA: 1786000000.0 |
| FY2019 | Aranesp: 1729000000.0, ENBREL: 5226000000.0, EPOGEN: 867000000.0, Kyprolis: 1044000000.0, Neulasta: 3221000000.0, Other Products: 4959000000.0, Product and Service, Other: 1158000000.0, Prolia: 2672000000.0, Sensipar Mimpara: 551000000.0, XGEVA: 1935000000.0 |
| FY2020 | Aranesp: 1568000000.0, ENBREL: 4996000000.0, Kyprolis: 1065000000.0, Neulasta: 2293000000.0, Otezla: 2195000000.0, Other Products: 6574000000.0, Product and Service, Other: 1184000000.0, Prolia: 2763000000.0, Repatha (evolocumab): 887000000.0, XGEVA: 1899000000.0 |
| FY2021 | Aranesp: 1480000000.0, ENBREL: 4465000000.0, Kyprolis: 1108000000.0, Neulasta: 1734000000.0, Nplate: 1027000000.0, Otezla: 2249000000.0, Other Products: 5851000000.0, Product and Service, Other: 1682000000.0, Prolia: 3248000000.0, Repatha (evolocumab): 1117000000.0, XGEVA: 2018000000.0 |
| FY2022 | Aranesp: 1421000000.0, ENBREL: 4117000000.0, Evenity: 787000000.0, Kyprolis: 1247000000.0, Neulasta: 1126000000.0, Nplate: 1307000000.0, Otezla: 2288000000.0, Other Products: 5570000000.0, Product and Service, Other: 1522000000.0, Prolia: 3628000000.0, Repatha (evolocumab): 1296000000.0, XGEVA: 2014000000.0 |
| FY2023 | Aranesp: 1362000000.0, BLINCYTO: 861000000.0, ENBREL: 3697000000.0, Evenity: 1160000000.0, KRYSTEXXA: 272000000.0, Kyprolis: 1403000000.0, Nplate: 1477000000.0, Otezla: 2188000000.0, Other Products: 5263000000.0, Product and Service, Other: 1280000000.0, Prolia: 4048000000.0, Repatha (evolocumab): 1635000000.0, TEPEZZA: 448000000.0, Vectibix: 984000000.0, XGEVA: 2112000000.0 |
| FY2024 | Aranesp: 1342000000.0, BLINCYTO: 1216000000.0, ENBREL: 3316000000.0, EVENITY: 1563000000.0, KRYSTEXXA: 1185000000.0, Kyprolis: 1503000000.0, Nplate: 1456000000.0, Otezla: 2126000000.0, Other Products: 5630000000.0, Product and Service, Other: 1398000000.0, Prolia: 4374000000.0, Repatha (evolocumab): 2222000000.0, TEPEZZA: 1851000000.0, TEZSPIRE: 972000000.0, Vectibix: 1045000000.0, XGEVA: 2225000000.0 |
| FY2025 | Aranesp: 1389000000.0, BLINCYTO: 1559000000.0, ENBREL: 2226000000.0, EVENITY: 2100000000.0, KRYSTEXXA: 1340000000.0, Nplate: 1524000000.0, Otezla: 2265000000.0, Other Products: 7263000000.0, Product and Service, Other: 1603000000.0, Prolia: 4414000000.0, Repatha: 3016000000.0, TEPEZZA: 1903000000.0, TEZSPIRE: 1478000000.0, Vectibix: 1175000000.0, XGEVA: 2084000000.0 |
| Period | Value |
|---|---|
| FY2011 | Non-US: 1317000000.0, UNITED STATES: 3701000000.0 |
| FY2013 | Non-US: 4196000000.0, UNITED STATES: 14480000000.0 |
| FY2014 | Non-US: 4667000000.0, UNITED STATES: 15396000000.0 |
| FY2015 | Non-US: 4495000000.0, UNITED STATES: 17167000000.0 |
| FY2016 | Non-US: 4665000000.0, UNITED STATES: 18326000000.0 |
| FY2017 | Non-US: 4820000000.0, UNITED STATES: 18029000000.0 |
| FY2018 | Non-US: 5389000000.0, UNITED STATES: 18358000000.0 |
| FY2019 | Non-US: 6138000000.0, UNITED STATES: 17224000000.0 |
| FY2020 | Non-US: 6928000000.0, UNITED STATES: 18496000000.0 |
| FY2021 | Non-US: 7785000000.0, UNITED STATES: 18194000000.0 |
| FY2022 | Non-US: 7728000000.0, UNITED STATES: 18595000000.0 |
| FY2023 | Non-US: 8384000000.0, UNITED STATES: 19806000000.0 |
| FY2024 | Non-US: 9561000000.0, UNITED STATES: 23863000000.0 |
| FY2025 | Non-US: 10332000000.0, UNITED STATES: 26419000000.0 |
Insights · Dividends · Forecast · Financials · Learn